ASLANER AK, M. Et Al. 2023. THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY. XIV Eurasian Hematology Oncology Congress , 39.

ASLANER AK, M., SAHİP YESİRALİOĞLU, B., GEDÜK, A., UÇAR, M. A., HACIBEKİROĞLU, T., POLAT, M. G., ... KALPAKÇI, Y.(2023). THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY . XIV Eurasian Hematology Oncology Congress (pp.39).

ASLANER AK, MÜZEYYEN Et Al. "THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY," XIV Eurasian Hematology Oncology Congress, 2023

ASLANER AK, MÜZEYYEN A. Et Al. "THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY." XIV Eurasian Hematology Oncology Congress , pp.39, 2023

ASLANER AK, M. Et Al. (2023) . "THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY." XIV Eurasian Hematology Oncology Congress , p.39.

@conferencepaper{conferencepaper, author={MÜZEYYEN ASLANER AK Et Al. }, title={THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY}, congress name={XIV Eurasian Hematology Oncology Congress}, city={}, country={}, year={2023}, pages={39} }